Argatroban In Sodium Chloride is owned by Eagle Pharms.
Argatroban In Sodium Chloride contains Argatroban.
Argatroban In Sodium Chloride has a total of 2 drug patents out of which 0 drug patents have expired.
Argatroban In Sodium Chloride was authorised for market use on 29 June, 2011.
Argatroban In Sodium Chloride is available in injectable;intravenous dosage forms.
Argatroban In Sodium Chloride can be used as method of treating thrombosis, method of treating an argatroban treatable condition.
The generics of Argatroban In Sodium Chloride are possible to be released after 26 September, 2027.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7687516 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(4 years from now) | |
US7589106 | EAGLE PHARMS | Alcohol free formulation of argatroban |
Sep, 2027
(4 years from now) |
Drugs and Companies using ARGATROBAN ingredient
Market Authorisation Date: 29 June, 2011
Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis
Dosage: INJECTABLE;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic